Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Diabetic; Foot Ulcers
Interventions: Offloading, Dressing Application; Other
Lead sponsor: Musculoskeletal Transplant Foundation; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Roanoke, Virginia • Salem, Virginia

Conditions: Diabetes Mellitus, Ulcer, Diabetic Polyneuropathy
Interventions: personal dermal thermometer (DT), Device; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Tucson, Georgia

Conditions: Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
Interventions: SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device; Device
Lead sponsor: PolyNovo Biomaterials Pty Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Castro Valley, California • Fresno, California • Vista, California + 4 more

Conditions: Diabetic Foot Ulcers, Wound
Interventions: Topical Oxygen Chamber for Extremities; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Catheter-Related Infections, Pressure Injury
Interventions: Patient Safety Display; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Severe Ulcerative Colitis
Interventions: Visilizumab; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Ulcerative Colitis
Interventions: MMX Mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 6
States / cities: Little Rock, Arkansas • Anaheim, California • San Francisco, California + 3 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: Dual Layer Amniotic Membrane (DLAM). Artacent®; Biological
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Pembroke Pines, Florida + 12 more

Conditions: Ulcerative Colitis (UC)
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 114
States / cities: Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more

Conditions: Ulcerative Colitis
Interventions: Mesalamine; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 772 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 78
States / cities: Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 74 more

Conditions: Marginal Ulcers
Interventions: Omeprazole, Famotidine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Specific Carbohydrate diet (SCD); Other
Lead sponsor: David Suskind; Other
Eligibility: 8 Years to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ulcerative Colitis
Interventions: UCRI; Diagnostic Test
Lead sponsor: Glycominds, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Gastroduodenal Ulcerations, Erosion
Interventions: PL3100, Naproxen; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Diabetic Foot Ulcer, Foot Ulcer Chronic, DFU, Ulcer Foot, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, Leg Ulcers, Ulcer
Interventions: Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
Interventions: Sucralfate, Placebo, Acetaminophen, Ibuprofen; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Months to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Upper Gastrointestinal Hemorrhage
Interventions: Over-the-scope hemoclipping device, Standard endoscopic treatment; Device · Other
Lead sponsor: CURE Digestive Diseases Research Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Diabetic Foot
Interventions: Cubicin, Vancomycin; Drug
Lead sponsor: Clinical Alliance for Research & Education - Infectious Diseases, LLC.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Annandale, Virginia

Conditions: Ulcerative Colitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more

Conditions: Ulcerative Colitis, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Wounds, Wound of Skin, Wound Leg, Venous Leg Ulcer
Interventions: ALLEVYN Non-Adhesive; Device
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Interventions: ELU42 Topical Spray; Drug
Lead sponsor: Eluciderm Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: O'Fallon, Illinois • Springfield, Illinois • Oradell, New Jersey + 1 more

Conditions: Diabetic Foot Ulcer
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colitis, Ulcerative
Interventions: Low-dose MH002, High-dose MH002, Placebo; Drug
Lead sponsor: MRM Health NV; Industry
Eligibility: 16 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more

Search by objective public record fields.

Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers

Dermal Thermometry and Self-Care of High Risk Diabetic Patients

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

Topical Oxygen Therapy for Diabetic Wounds

Pilot Testing a Patient Safety Display in the Hospital Setting

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

Ulcer Prevention Study in Post Gastric Bypass Patients

Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

Treatment of Foot and Leg Ulcers Using a Laser

Confirmatory Clinical Study in Active Ulcerative Colitis